Avacta Group Plc (AVCTF)
USD 0.52
(-16.56%)
USD 0.52
(-16.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.95 Million GBP | 58.65% |
| 2022 | 3.75 Million GBP | 165.79% |
| 2021 | 1.41 Million GBP | -19.41% |
| 2020 | 1.75 Million GBP | 171.21% |
| 2019 | 646 Thousand GBP | 0.0% |
| 2018 | - GBP | 0.0% |
| 2017 | - GBP | 0.0% |
| 2016 | - GBP | 0.0% |
| 2015 | - GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| 2013 | - GBP | 0.0% |
| 2012 | - GBP | 0.0% |
| 2011 | - GBP | -100.0% |
| 2010 | 5000.00 GBP | -72.22% |
| 2009 | 18 Thousand GBP | -40.0% |
| 2008 | 30 Thousand GBP | -26.83% |
| 2007 | 41 Thousand GBP | 0.0% |
| 2006 | - GBP | 0.0% |
| 2005 | - GBP | -100.0% |
| 2004 | 25 Thousand GBP | 0.0% |
| 2003 | - GBP | 0.0% |
| 2002 | - GBP | 0.0% |
| 2001 | - GBP | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 4.94 Million GBP | 0.0% |
| 2023 Q3 | 5.95 Million GBP | 20.5% |
| 2023 FY | 5.95 Million GBP | 58.65% |
| 2023 Q4 | 5.95 Million GBP | 0.0% |
| 2023 Q1 | 4.94 Million GBP | 31.65% |
| 2022 Q4 | 3.75 Million GBP | 0.0% |
| 2022 FY | 3.75 Million GBP | 165.79% |
| 2022 Q1 | 3.97 Million GBP | 181.37% |
| 2022 Q2 | 3.97 Million GBP | 0.0% |
| 2022 Q3 | 3.75 Million GBP | -5.54% |
| 2021 Q3 | 1.41 Million GBP | -11.69% |
| 2021 Q4 | 1.41 Million GBP | 0.0% |
| 2021 FY | 1.41 Million GBP | -19.41% |
| 2021 Q1 | 1.59 Million GBP | -8.73% |
| 2021 Q2 | 1.59 Million GBP | 0.0% |
| 2020 Q3 | 1.75 Million GBP | 208.45% |
| 2020 Q1 | 568 Thousand GBP | 0.0% |
| 2020 Q2 | 568 Thousand GBP | 0.0% |
| 2020 Q4 | 1.75 Million GBP | 0.0% |
| 2020 FY | 1.75 Million GBP | 171.21% |
| 2019 FY | 646 Thousand GBP | 0.0% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 Q2 | - GBP | 0.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2018 FY | - GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 Q1 | - GBP | 0.0% |
| 2017 Q1 | - GBP | 0.0% |
| 2017 FY | - GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2017 Q3 | - GBP | 0.0% |
| 2017 Q2 | - GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2016 FY | - GBP | 0.0% |
| 2016 Q3 | - GBP | 0.0% |
| 2016 Q4 | - GBP | 0.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2015 FY | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 Q1 | - GBP | 0.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2014 Q3 | - GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| 2014 Q1 | - GBP | 0.0% |
| 2014 Q2 | - GBP | 0.0% |
| 2014 Q4 | - GBP | 0.0% |
| 2013 Q4 | - GBP | 0.0% |
| 2013 Q1 | - GBP | 0.0% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2013 Q3 | - GBP | 0.0% |
| 2012 Q4 | - GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 Q3 | - GBP | 0.0% |
| 2012 FY | - GBP | 0.0% |
| 2011 FY | - GBP | -100.0% |
| 2011 Q4 | - GBP | 0.0% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 Q4 | - GBP | 0.0% |
| 2010 Q2 | 5000.00 GBP | 0.0% |
| 2010 FY | 5000.00 GBP | -72.22% |
| 2009 Q4 | 10 Thousand GBP | 0.0% |
| 2009 Q2 | 18 Thousand GBP | 0.0% |
| 2009 FY | 18 Thousand GBP | -40.0% |
| 2008 FY | 30 Thousand GBP | -26.83% |
| 2008 Q4 | 23 Thousand GBP | 0.0% |
| 2008 Q2 | 30 Thousand GBP | 0.0% |
| 2007 Q4 | 35 Thousand GBP | 0.0% |
| 2007 FY | 41 Thousand GBP | 0.0% |
| 2006 FY | - GBP | 0.0% |
| 2006 Q1 | - GBP | 0.0% |
| 2006 Q3 | - GBP | 0.0% |
| 2005 FY | - GBP | -100.0% |
| 2005 Q3 | - GBP | 0.0% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 FY | 25 Thousand GBP | 0.0% |
| 2004 Q1 | 25 Thousand GBP | 0.0% |
| 2004 Q3 | - GBP | 0.0% |
| 2003 FY | - GBP | 0.0% |
| 2003 Q3 | - GBP | 0.0% |
| 2002 FY | - GBP | 0.0% |
| 2001 FY | - GBP | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 8.26 Million USD | 27.953% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -3377.194% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -239.167% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -7342.5% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -2141.421% |
| CSL Limited | 11.23 Billion USD | 99.947% |
| Evofem Biosciences, Inc. | 8000.00 USD | -74325.0% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -3879.574% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 70.687% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 71.524% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -10053.133% |
| Mesoblast Limited | 100.29 Million USD | 94.064% |
| Marizyme, Inc. | 667.12 Thousand USD | -792.481% |
| Genus plc | 228.2 Million USD | 97.391% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 96.416% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -107918.868% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -169.412% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -324.396% |
| IMV Inc. | 27.39 Million USD | 78.269% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -9.721% |
| MultiCell Technologies, Inc. | 36.43 USD | -16343572.797% |
| ONE Bio Corp. | 592.19 Thousand USD | -905.407% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 89.294% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -167.475% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -384.711% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -973.586% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -23434.527% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -213.621% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -1749.068% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -3869.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -3525.955% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 61.222% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -133517.594% |
| Genscript Biotech Corporation | 287.12 Million USD | 97.926% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -4614.098% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2496.7% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -2492.178% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -559486.466% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -3879.574% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -4122.695% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 23.862% |
| SYBLEU INC | 300 Thousand USD | -1884.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -1513.336% |
| International Stem Cell Corporation | 445 Thousand USD | -1237.978% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | 26.945% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -1202.845% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -412.834% |
| PureTech Health plc | 18.25 Million USD | 67.375% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -3869.333% |
| IXICO plc | 275 Thousand USD | -2065.091% |
| IntelGenx Technologies Corp. | 11.83 Million USD | 49.709% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 77.369% |
| CSL Limited | 11.23 Billion USD | 99.947% |
| Cellectis S.A. | 36.21 Million USD | 83.558% |